Treatment of acute coronary syndrome with an exendin

Abstract

The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.

1 - 47 . (canceled)  
     
     
         48 . A method of treating a patient suffering from acute coronary syndrome, comprising administering to the patient a therapeutically effective amount of an exendin.  
     
     
         49 . (canceled)  
     
     
         50 . The method of  claim 48 , wherein the exendin is exendin-3.  
     
     
         51 . The method of  claim 48 , wherein the exendin is administered in at least one dose.  
     
     
         52 . The method of  claim 48 , wherein the exendin is administered continuously.  
     
     
         53 . The method of  claim 48 , wherein glucose, a potassium salt, or a combination thereof, is co-administered with the exendin.  
     
     
         54 . A method for treatment of a patient suffering from one or more conditions selected from the group consisting of unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial infarction, acute myocardial infarction, ischemic heart disease, and stable angina, comprising administering to said individual a therapeutically effective amount of an exendin, wherein said administration is after the onset of one or more of the following symptoms: chest pain lasting longer than 15 minutes, chest pain at rest, chest pain following minimal exertion, nausea, shortness of breath, palpitations, or dizziness  
     
     
         55 . The method of  claim 54 , wherein the exendin is exendin-4.  
     
     
         56 . The method of  claim 54 , wherein the exendin is exendin-3.  
     
     
         57 . The method of  claim 54 , wherein the exendin is administered in at least one dose.  
     
     
         58 . The method of  claim 54 , wherein the exendin is administered continuously.  
     
     
         59 . The method of  claim 54 , wherein glucose, a potassium salt, or a combination thereof, is co-administered with the exendin.  
     
     
         60 . A method for increasing the time during which thrombolytic therapy will be effective following the first symptoms of cardiac distress, comprising administering a therapeutically effective amount of an exendin after the onset of one or more of the following symptoms: chest pain lasting longer than 15 minutes, chest pain at rest, chest pain following minimal exertion, nausea, shortness of breath, palpitations, or dizziness.  
     
     
         61 . The method of  claim 60 , wherein the exendin is exendin-4.  
     
     
         62 . The method of  claim 60 , wherein the exendin is exendin-3.  
     
     
         63 . The method of  claim 60 , wherein the exendin is administered in at least one dose.  
     
     
         64 . The method of  claim 60 , wherein the exendin is administered continuously.  
     
     
         65 . The method of  claim 60 , wherein glucose, a potassium salt, or a combination thereof, is co-administered with the exendin.